# Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies

> **NCT02473224** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 44 (actual)

## Conditions studied

- Gastroenteritis Norovirus

## Interventions

- **BIOLOGICAL:** Norovirus GII.2 Challenge
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02473224
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-28
- **Primary completion:** 2018-11-27
- **Final completion:** 2018-11-27
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2018-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02473224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02473224, "Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02473224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*